COVID-19: Locked in a pro-inflammatory state
Macrophages absorbing cells infected with viable SARS-CoV-2 particles fail to transition into an anti-inflammatory state, potentially contributing to a damaging immune reaction linked to severe forms of COVID-19.
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
In the last two and a half years, scientists all over the world have worked relentlessly to develop treatments and vaccines against SARS-CoV-2, the virus causing COVID-19. While considerable progress has been made identifying key properties of the virus, several fundamental questions remain. For example, it is still unclear why some people develop long COVID-19, or why others are asymptomatic.
Previous research has shown that some patients with COVID-19 can experience a cytokine storm, which is characterized by a high concentration of pro-inflammatory proteins called cytokines (Wong, 2021; Ragab et al., 2020). Cytokine storms can be an indicator of a poor disease prognosis, and research indicates that they contribute to long-term, and sometimes life-threatening, conditions in patients with long COVID-19 (Rai et al., 2021). Now, in eLife, Larissa Cunha and colleagues at the Universidade de São Paulo – including Ana Salina, Douglas dos-Santos, Tamara Rodrigues, and Marlon Fortes-Rocha as joint first authors – report new insights into how COVID-19 may cause cytokine storms (Salina et al., 2022).
Immune cells called macrophages are the major cell type responsible for cytokine storms in COVID-19 (Merad and Martin, 2020). Typically, they migrate to infected or damaged sites in the body, and upon contact with bacteria, viruses, or chemicals emitted by dying cells, produce proinflammatory cytokines (Figure 1). These, in turn, strengthen the response of other immune cells. Once the pathogens have been eliminated, macrophages stop producing proinflammatory cytokines and instead start releasing anti-inflammatory signals, which promote healing.
Figure 1
Phenotype change of macrophages in response to apoptotic cells.
An epithelial cell (shown in red) attacked by SARS-CoV-2 (white) activates immune cells, known as macrophages (yellow), via the cytokine interferon gamma (blue receptor). The macrophages then differentiate into a proinflammatory state M1 (lilac) and secrete proinflammatory cytokines to activate other immune responses. M1 macrophages also help to clear cell debris and virus particles by engulfing the infected cells, a process known as efferocytosis. Normally, absorbing apoptotic (dying) cells infected with a virus causes M1 macrophages to change into M2 macrophages (green), which secrete anti-inflammatory cytokines. These in turn, stimulate fibroblasts (brown) to help regenerate damaged tissues. However, macrophages that have engulfed viable SARS-CoV-2 particles do not change into the anti-inflammatory phenotype. They also are less able to absorb pathogens and cell debris, which leads to prolonged inflammation.
Image credit: The figure was created with biorender.com.
Previous research has shown that during this transition, macrophages change their phenotype from a proinflammatory state M1 to an anti-inflammatory one, M2 (Kohno et al., 2021). It was, however, unclear how they achieve this. To find out if the same transition happens after infection with COVID-19, Salina et al. used apoptotic lung and kidney cells (that is, cells undergoing regulated cell death) containing either viable SARS-CoV-2 particles, inactivated viral particles, or sterile culture medium. They then investigated if and how engulfing apoptotic cells, a process known as efferocytosis, affects the phenotypic change of the macrophages.
The results revealed that SARS-CoV-2 prevented M1 macrophages from changing into M2 macrophages, thereby increasing the inflammatory potential of these immune cells. In the experiments, only cells infected with viable SARS-CoV-2 blocked the M1 macrophages from changing into M2 macrophages and increased the amount of proinflammatory cytokines produced, such as IL-6. Experiments with another virus species did not achieve the same outcome, suggesting that the overproduction of IL-6 may be specific to SARS-CoV-2.
Salina et al. further tested the effect of antiviral drugs targeting the transcription process of viral RNA and found that viral RNAs appear to play a significant role in preventing macrophages changing into the anti-inflammatory state. Treating macrophages with the antiviral drug Remdesivir after they had engulfed cells with viable SARS-CoV-2 reduced the production of IL-6.
These observations indicate that viral RNAs – once taken up by macrophages – arrest the immune cells to remain in the M1 phenotype, which may contribute to the cytokine storm seen in patients with COVID-19. Moreover, absorbing cells containing viable SARS-CoV-2 reduced the number of proteins responsible for recognizing apoptotic cells. This led to a build-up of cell debris and apoptotic cells.
To find out how defective efferocytosis affects the pathogenesis of COVID-19, Salina et al. stained lung tissue samples from COVID-19 patients with immunofluorescent dyes and assessed the expression of efferocytosis receptor proteins. This revealed that lung samples had a lower level of gene expression linked to efferocytosis, which lead to a reduced clearance of cell debris. It also showed that the production of cytokines was dysfunctional, suggesting that SARS-CoV-2 over-activates macrophages in the lungs. This in turn, led to severe inflammation and impaired tissue regeneration. Furthermore, the residual cell debris induced signaling molecules that activated a type of immune cells, called monocytes, to become M1 macrophages. Combined, these changes could increase inflammation even further and may prolong a dysfunctional immune response long after recovery, potentially leading to long COVID-19 syndromes.
While many questions around COVID-19 and its long-term effects warrant further research, the study of Salina et al. provides valuable insights into the complex mechanisms of cytokine storms and may open new avenues for developing treatment plans for patients with severe COVID-19 (Misra et al., 2021; Gracia-Ramos et al., 2021; Ma et al., 2022; Batlle et al., 2022; Yeung et al., 2021).
References
-
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophagesNature Reviews Immunology 20:355–362.https://doi.org/10.1038/s41577-020-0331-4
-
The COVID-19 Cytokine Storm; What We Know So FarFrontiers in Immunology 11:1446.https://doi.org/10.3389/fimmu.2020.01446
-
Post covid 19 pulmonary fibrosis is it real threat?The Indian Journal of Tuberculosis 68:330.https://doi.org/10.1016/j.ijtb.2020.11.003
-
Inflammation in COVID-19: from pathogenesis to treatmentInternational Journal of Clinical and Experimental Pathology 14:831–844.
Article and author information
Author details
Publication history
- Version of Record published: July 7, 2022 (version 1)
Copyright
© 2022, Wang Chau and Sugimura
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,487
- views
-
- 255
- downloads
-
- 4
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
COVID-19: Locked in a pro-inflammatory state
eLife 11:e80699.
https://doi.org/10.7554/eLife.80699
Further reading
-
- Immunology and Inflammation
Trained immunity is the long-term functional reprogramming of innate immune cells, which results in altered responses toward a secondary challenge. Despite indoxyl sulfate (IS) being a potent stimulus associated with chronic kidney disease (CKD)-related inflammation, its impact on trained immunity has not been explored. Here, we demonstrate that IS induces trained immunity in monocytes via epigenetic and metabolic reprogramming, resulting in augmented cytokine production. Mechanistically, the aryl hydrocarbon receptor (AhR) contributes to IS-trained immunity by enhancing the expression of arachidonic acid (AA) metabolism-related genes such as arachidonate 5-lipoxygenase (ALOX5) and ALOX5 activating protein (ALOX5AP). Inhibition of AhR during IS training suppresses the induction of IS-trained immunity. Monocytes from end-stage renal disease (ESRD) patients have increased ALOX5 expression and after 6 days training, they exhibit enhanced TNF-α and IL-6 production to lipopolysaccharide (LPS). Furthermore, healthy control-derived monocytes trained with uremic sera from ESRD patients exhibit increased production of TNF-α and IL-6. Consistently, IS-trained mice and their splenic myeloid cells had increased production of TNF-α after in vivo and ex vivo LPS stimulation compared to that of control mice. These results provide insight into the role of IS in the induction of trained immunity, which is critical during inflammatory immune responses in CKD patients.
-
- Cancer Biology
- Immunology and Inflammation
Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and chemotherapy agents targeting pyrimidine metabolism are the backbone of treatment for many cancers. Dihydroorotate dehydrogenase (DHODH) is an essential enzyme in the de novo pyrimidine biosynthesis pathway that can be targeted by clinically approved inhibitors. However, despite robust preclinical anticancer efficacy, DHODH inhibitors have shown limited single-agent activity in phase 1 and 2 clinical trials. Therefore, novel combination therapy strategies are necessary to realize the potential of these drugs. To search for therapeutic vulnerabilities induced by DHODH inhibition, we examined gene expression changes in cancer cells treated with the potent and selective DHODH inhibitor brequinar (BQ). This revealed that BQ treatment causes upregulation of antigen presentation pathway genes and cell surface MHC class I expression. Mechanistic studies showed that this effect is (1) strictly dependent on pyrimidine nucleotide depletion, (2) independent of canonical antigen presentation pathway transcriptional regulators, and (3) mediated by RNA polymerase II elongation control by positive transcription elongation factor B (P-TEFb). Furthermore, BQ showed impressive single-agent efficacy in the immunocompetent B16F10 melanoma model, and combination treatment with BQ and dual immune checkpoint blockade (anti-CTLA-4 plus anti-PD-1) significantly prolonged mouse survival compared to either therapy alone. Our results have important implications for the clinical development of DHODH inhibitors and provide a rationale for combination therapy with BQ and immune checkpoint blockade.
